Daniel J Lips
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Daniel J Lips has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
J.C. van der Linden
4 shared publications- K. Bosscha
Jeroen Bosch Hospital
4 shared publications - Cornelis J. H. van de Velde
Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
3 shared publications - Gerrit-Jan Liefers
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
3 shared publications J.F.M. Pruijt
3 shared publicationsB. Koebruqqe
2 shared publications
Latest Publications
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S427
6117 POSTER Use of Adjuvant Chemotherapy in High-risk Stage II Colonic Cancer Patients in the Netherlands 2000-2009
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S427
6117 POSTER Use of Adjuvant Chemotherapy in High-risk Stage II Colonic Cancer Patients in the Netherlands 2000-2009
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S400
6030 POSTER The Number of High Risk Factors is Related to Outcome in Stage II Colonic Cancer Patients
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S400
6030 POSTER The Number of High Risk Factors is Related to Outcome in Stage II Colonic Cancer Patients
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S456-S457
6551 POSTER Improved Lymph Node Retrieval in Gastric Cancer – Preliminary Positive Results of the DoCCS-study
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S456-S457
6551 POSTER Improved Lymph Node Retrieval in Gastric Cancer – Preliminary Positive Results of the DoCCS-study
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S427
6116 POSTER Trends in Incidence, Treatment and Survival of Stage II T4 Colon Cancer Patients
- 30 September 2011
- Published by Elsevier in European Journal of Cancer
- Vol. 47, S427
6116 POSTER Trends in Incidence, Treatment and Survival of Stage II T4 Colon Cancer Patients
- Open Access
- 11 May 2011
- Published by Springer Nature in BMC Surgery
- Vol. 11 (1) , 11
The influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute⊕ Study
The presence of lymph node metastases remains the most reliable prognostic predictor and the gold indicator for adjuvant treatment in colon cancer (CC). In spite of a potentially curative resection, 20 to 30% of CC patients testing negative for lymph node metastases (i.e. pN0) will subsequently develop locoregional and/or systemic metastases within 5 years. The presence of occult nodal isolated tumor cells (ITCs) and/or micrometastases (MMs) at the time of resection predisposes CC patients to high risk for disease recurrence. These pN0micro+ patients harbouring occult micrometastases may benefit from adjuvant treatment. The purpose of the present study is to delineate the subset of pN0 patients with micrometastases (pN0micro+) and evaluate the benefits from adjuvant chemotherapy in pN0micro+ CC patients. EnRoute+ is an open label, multicenter, randomized controlled clinical trial. All CC patients (age above 18 years) without synchronous locoregional lymph node and/or systemic metastases (clinical stage I-II disease) and operated upon with curative intent are eligible for inclusion. All resected specimens of patients are subject to an ex vivo sentinel lymph node mapping procedure (SLNM) following curative resection. The investigation for micrometastases in pN0 patients is done by extended serial sectioning and immunohistochemistry for pan-cytokeratin in sentinel lymph nodes which are tumour negative upon standard pathological examination. Patients with ITC/MM-positive sentinel lymph nodes (pN0micro+) are randomized for adjuvant chemotherapy following the CAPOX treatment scheme or observation. The primary endpoint is 3-year disease free survival (DFS). The EnRoute+ study is designed to improve prognosis in high-risk stage I/II pN0 micro+ CC patients by reducing disease recurrence by adjuvant chemotherapy. ClinicalTrials.gov: NCT01097265
- 11 May 2011
- Published by Springer Nature in BMC Surgery
- Vol. 11 (1) , 11
Open AccessThe influence of micrometastases on prognosis and survival in stage I-II colon cancer patients: the Enroute⊕ Study
The presence of lymph node metastases remains the most reliable prognostic predictor and the gold indicator for adjuvant treatment in colon cancer (CC). In spite of a potentially curative resection, 20 to 30% of CC patients testing negative for lymph node metastases (i.e. pN0) will subsequently develop locoregional and/or systemic metastases within 5 years. The presence of occult nodal isolated tumor cells (ITCs) and/or micrometastases (MMs) at the time of resection predisposes CC patients to high risk for disease recurrence. These pN0micro+ patients harbouring occult micrometastases may benefit from adjuvant treatment. The purpose of the present study is to delineate the subset of pN0 patients with micrometastases (pN0micro+) and evaluate the benefits from adjuvant chemotherapy in pN0micro+ CC patients. EnRoute+ is an open label, multicenter, randomized controlled clinical trial. All CC patients (age above 18 years) without synchronous locoregional lymph node and/or systemic metastases (clinical stage I-II disease) and operated upon with curative intent are eligible for inclusion. All resected specimens of patients are subject to an ex vivo sentinel lymph node mapping procedure (SLNM) following curative resection. The investigation for micrometastases in pN0 patients is done by extended serial sectioning and immunohistochemistry for pan-cytokeratin in sentinel lymph nodes which are tumour negative upon standard pathological examination. Patients with ITC/MM-positive sentinel lymph nodes (pN0micro+) are randomized for adjuvant chemotherapy following the CAPOX treatment scheme or observation. The primary endpoint is 3-year disease free survival (DFS). The EnRoute+ study is designed to improve prognosis in high-risk stage I/II pN0 micro+ CC patients by reducing disease recurrence by adjuvant chemotherapy. ClinicalTrials.gov: NCT01097265
- Open Access
- 20 January 2011
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 98 (3) , 462-463
Surgeons and selection of adjuvant therapy for node-negative colonic cancer (Br J Surg 2010; 97: 1459–1460)
- 20 January 2011
- Published by Oxford University Press (OUP) in British Journal of Surgery
- Vol. 98 (3) , 462-463
Open AccessSurgeons and selection of adjuvant therapy for node-negative colonic cancer (Br J Surg 2010; 97: 1459–1460)